Significance of epiregulin expression induced by KRAS or EGFR mutation in non-small-cell lung cancer
Project/Area Number |
23591134
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | Gunma University |
Principal Investigator |
SUNAGA NORIAKI 群馬大学, 医学部附属病院, 助教 (70400778)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
Keywords | 非小細胞肺癌 / KRAS遺伝子変異 / 分子標的治療 / エピレギュリン / EGFR遺伝子変異 / 予後不良因子 / Epiregulin |
Research Abstract |
EREG is overexpressed in non-small-cell lung cancers (NSCLCs) harboring KRAS, BRAF or EGFR mutations compared with small-cell lung cancers (SCLCs) or NSCLCs with wild-type KRAS/BRAF/EGFR. EREG expression was reduced by knockdown of mutant KRAS, BRAF or EGFR or by MEK or ERK inhibition in NSCLC cells. EREG expression positively correlated with KRAS copy number in KRAS-mutant NSCLCs. EREG was predominantly expressed in NSCLC tumors with pleural involvement, lymphatic permeation or vascular invasion and in KRAS-mutant adenocarcinomas. EREG expression is an independent prognostic marker and EREG overexpression along with KRAS mutations correlated with an unfavorable prognosis for lung adenocarcinoma patients. In KRAS-mutant and EREG overexpressing NSCLCs, EREG attenuation suppressed tumor growth and induced apoptosis. These results suggest that oncogenic KRAS-induced EREG overexpression contributes to an aggressive phenotype and could be a therapeutic target in oncogenic KRAS-driven NSCLC.
|
Report
(4 results)
Research Products
(10 results)
-
[Journal Article] Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.2012
Author(s)
Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M.
-
Journal Title
Oncogene
Volume: 印刷中
Issue: 34
Pages: 4034-4042
DOI
Related Report
Peer Reviewed
-
-
-
[Presentation] Clinicopathological and biological significance of epiregulin expression in non-small cell lung cancer.2013
Author(s)
Sunaga N, Tomizawa Y, Shimizu K, Imai H, Takahashi G, Kakegawa S, Ohtaki Y, Nagashima T, Kawashima O, Shames DS, Girard L, Soh J, Sato M, Kaira K, Hisada T, Gazdar AF, Minna JD, Yamada M.
Organizer
15th World Conference on Lung Cancer
Place of Presentation
Sydney, Australia
Related Report
-
-
-
-
-
-